ClinicalTrials.gg
Enrolling by invitationNCT04074356Updated Oct 21, 2026

Non-invasive Markers of Esophageal Function in Adults

An interventional study of Clinical measure questionnaires and EESG in Dysphagia, sponsored by Vanderbilt University Medical Center. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 21, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 230 studies in Deglutition Disorders with a site in United States — 43 open to participants now, 48 under way, none of them phase 3. Deglutition Disorders · United States.

Planned enrollment
47th of 165
90 · median 50
Started
2019
with 4 others
No phase
118 of 230
32 open now
Primary completion
2026-12
later than 17 of 47 live
Registered
144th of 230
by date
Lead sponsor
5 of 230
Vanderbilt University Medical Center

Among the 230 studies in Deglutition Disorders with a site in United States, this one is the 47th largest by planned enrollment of the 165 interventional ones that give a count, is one of 5 that started in 2019, is one of 118 with no phase, reaches primary completion later than 17 of the 47 other live ones, and was the 144th registered.

Deglutition Disorders

875 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.

Browse Deglutition Disorders studies →

Open to participants now

43 of the 230 studies in Deglutition Disorders with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 137 Deglutition Disorders studies recruiting now, 75 (55%) set no upper age limit and 26 (19%) stop at 75 or younger; 15 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Deglutition Disorders with a site in United States, or all of them as a file.
02

Study summary

The investigator proposes to study electrical activity reflective of esophageal motility in adults noninvasively by the use of multichannel electroesophagogram (EESG) and magnetoesophagogram (MESG) recordings.

Read the detailed description

Dysphagia, or difficulty with swallowing, is a common symptom affecting nearly 9.4 million individuals or 4% of the US population. High resolution esophageal manometry is currently considered the gold standard test for evaluation and diagnosis of esophageal motility disorders, but given that it requires trans-nasal placement in a conscious patient, this test is highly uncomfortable and associated with significant patient dissatisfaction. There are currently no noninvasive tests or markers available to test esophageal function and motility.

In the upper gastrointestinal system, as in the heart, disruption of the electrical syncytium in disease produces measurable dysrhythmia. Recent modifications of the standard electrogastrogram (EGG) that have increased the number of leads to 25 (termed high-resolution EGG) have allowed enhanced spatio-temporal resolution of electric slow wave activity, and newer analytic techniques. Additionally, the magnetogastrogram (MGG) overcomes many of the inherent limitations of the standard EGG. The goal of this proposal is to harness similar technologies applied to the esophagus to develop high-resolution electroesophagogram (EESG) and magnetoesophagogram (MESG) as noninvasive clinical methods to quantify esophageal function and motility disorders, which could guide intervention for a large number of adult patients.

The main aims in this proposal are to develop a mathematical model of esophageal function and characterize phenotypes of esophageal motility disorders using EESG/MESG in healthy controls and esophageal dysmotility patients and determine how EESG/MESG rhythm and pattern abnormalities relate to physiologic function.

03

Conditions studied

  • Dysphagia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years of age who are undergoing HRM for routine standard of care evaluation for esophageal motility.
  • Normal control participants (ages ≥ 18 years) who have no known gastrointestinal complications.

Exclusion criteria

Exclusion Criteria:

  • Those with claustrophobia who cannot lie still under the SQUID for the length of time required
  • Due to interference with signal acquisition, subjects with to undergoing an MRI scan as noted in the MRI Safety checklist by Vanderbilt University Medical Center (such as with heart pacemakers, metal implants, or metal chips or clips) will not undergo SQUID, but can still be eligible to do cutaneous EESG.
  • Morbid obesity (these patients are potentially unable to lie under the current generation of SQUID devices)
  • Patients with a history of cardiac arrhythmias or taking anticoagulants will be excluded
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Healthy Controls

    Healthy volunteers with no known gastrointestinal complications will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).

    Other: Clinical measure questionnaires · Diagnostic Test: EESG · Diagnostic Test: MESG

  • Active comparator
    Achalasia subjects

    Subjects who have undergone standard of care high resolution manometry that results in a diagnosis of achalasia will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).

    Other: Clinical measure questionnaires · Diagnostic Test: EESG · Diagnostic Test: MESG · Diagnostic Test: High resolution manometry (HRM)

  • Active comparator
    Hypercontractile/spastic disorder subjects

    Subjects who have undergone standard of care high resolution manometry that results in a diagnosis of hypercontractile/spastic disorder will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).

    Other: Clinical measure questionnaires · Diagnostic Test: EESG · Diagnostic Test: MESG · Diagnostic Test: High resolution manometry (HRM)

Interventions

  • OtherClinical measure questionnaires

    Collection of patient reported symptoms and perception of health

  • Diagnostic testEESG

    Use of silver-silver chloride cutaneous electrogastrogram (EGG) electrodes to get myoelectrical readings

  • Diagnostic testMESG

    MESG measures spatiotemporal properties of magnetic fields from the esophageal slow wave and allows characterization of the propagation of the slow wave in addition to evaluation of its frequency and power distribution

    Also known as: SQUID magnetometer

  • Diagnostic testHigh resolution manometry (HRM)

    Dysphagia subjects will have undergone standard of care HRM to determine placement in the achalasia or hypercontractile/spastic disorder arms

06

What researchers measure

Primary outcomes

  1. Presence of diagnostic pattern

    EESG and MESG wave patterns will be used to see if there is a diagnostic pattern that helps identify normal function vs. the motility disorders (achalasia or hypercontractile/spastic disorders)

    Time frame: 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The investigators agree to the timely release and sharing of information to be no later than the acceptance for publication of the main findings from the final data set. Investigators are also committed to ensuring that all data are free of identifiers that would permit linkage to individual research participants as well as variables that could lead to deductive disclosure of the identity of individual subjects.

Time frame: Immediately following publication. No end date.

Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Dec 2026, 87 months after the start.

Of 290 non-industry interventional studies with no phase under Deglutition Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 87 months is above that.

Counting every sponsor, half of 299 studies reached it within 21 months; a quarter within 10 and three quarters within 38.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2019
First posted
Aug 30, 2019
StartActual
Sep 4, 2019
Primary completionEst.
Dec 30, 2026was Sep 2026
CompletionEst.
Dec 30, 2026was Sep 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Dec 30, 2026
Oct 21, 2026
Study completion
Sep 2026→Dec 30, 2026
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Primary completion Sep 2026→Dec 30, 2026
    Study completion Sep 2026→Dec 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04074356
Responsible party
Dhyanesh Patel (Principal Investigator, Vanderbilt University Medical Center) — Principal investigator
First posted
Aug 30, 2019
Start date
Sep 4, 2019
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 21, 2026

Study contacts

Dhyanesh Patel, MD
principal investigator · Vanderbilt University Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion